Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : alpha L Idosiduronase
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : JR-171 is a blood-brain-barrier (BBB)-penetrating form recombinant α-L-iduronidase that was developed using JCR’s proprietary J-Brain Cargo® BBB technology.
Brand Name : JR-171
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 30, 2021
Lead Product(s) : alpha L Idosiduronase
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : alpha L Idosiduronase
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
JCR Announces First Patient Dosed in Phase1/2 Global Clinical Trial of JR-171 for MPS I
Details : In this study, MPS I patients will be treated with JR-171 for at most 12 weeks to evaluate the safety of JR-171 as the primary endpoint and exploratory efficacy and pharmacokinetics as secondary endpoints.
Brand Name : JR-171
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 30, 2020
Lead Product(s) : alpha L Idosiduronase
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : alpha L Idosiduronase
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : JR-171 is a blood-brain-barrier (BBB)-penetrating recombinant α-L-iduronidase, the product candidate for the treatment of patients with MPS I, to which J-Brain Cargo®, JCR’s proprietary BBB penetration technology, is applied.
Brand Name : JR-171
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 31, 2020
Lead Product(s) : alpha L Idosiduronase
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?